iOrganBio is a technology company.
iOrganBio has raised $2.0M across 1 funding round.
iOrganBio has raised $2.0M in total across 1 funding round.
iOrganBio has raised $2.0M in total across 1 funding round.
iOrganBio's investors include Draper Associates, First Star Ventures, Hustle Fund, Innospark Ventures, Locus Ventures.
iOrganBio is an early‑stage biotechnology company building an AI‑driven platform, CellForge™, to make the production of engineered human cells and organoids predictable, reproducible, and scalable for drug discovery, disease modeling, and cell therapies.[2][4]
High‑Level Overview
iOrganBio’s mission is to industrialize cell manufacturing by combining AI prediction, biological sensing, and automated 3D incubation to produce defined cellular products at scale.[2][4] Their investment/operational support comes from a $2M seed round led by First Star Ventures with participation from IndieBio, Cape Fear BioCapital, Terasaki Institute and others, reflecting early VC validation of the model and access to accelerator resources through IndieBio.[3] The company focuses on sectors at the intersection of regenerative medicine, in vitro disease models/drug discovery, and cell therapy manufacturing.[4][3] By offering a platform that promises reproducible, high‑volume access to diverse cell types, iOrganBio could lower a major bottleneck for both academic and industrial users and thereby accelerate downstream startup and pharma programs that rely on consistent human cellular models.[1][4]
Origin Story
iOrganBio was founded in 2024 by Dr. Daniel Delubac (CEO), Dr. Shuibing Chen (Weill Cornell Medicine), and Prof. Xiling Shen (MD Anderson/Terasaki Institute), building on science originating in Dr. Chen’s lab at Weill Cornell Medicine.[4][1] The team combined expertise across human pluripotent stem cell (hPSC) differentiation, automation, and manufacturing to create CellForge™, an AI‑controlled, closed‑loop 3D culture platform developed to solve reproducibility and scale challenges in cell engineering.[1][4] Early traction includes emergence from stealth with $2M in seed funding and demonstrations such as using CellForge to identify beta islet–like cells for pancreas model work, which the company cites as an initial technical validation.[1][3]
Core Differentiators
Role in the Broader Tech Landscape
iOrganBio is riding multiple converging trends: the move toward programmable/engineered biology, the application of AI to wet‑lab optimization, and industry demand for reliable human cell sources for drug discovery and regenerative medicine.[2][4] Timing matters because the cell therapy field increasingly requires scalable, well‑defined manufacturing solutions and because AI/automation tools have matured to enable closed‑loop biological experiments.[1][4] Market forces in their favor include rising R&D investment in human‑relevant models, pressure to reduce variability and cost in cell‑based products, and growing venture and institutional support for platform companies that can serve many downstream users.[3][6] If successful, iOrganBio could influence the ecosystem by reducing entry barriers for startups and academic labs that need high‑quality human cells, and by providing a standardized manufacturing approach that partners and larger biopharma firms might adopt.[1][3]
Quick Take & Future Outlook
Near term, expect iOrganBio to: refine CellForge’s libraries of defined cell profiles, publish technical validations, expand partnerships with academic labs and biopharma, and use IndieBio/VC networks to scale commercialization efforts after the seed round.[2][3] Over the next 2–5 years, key determinants of success will be demonstrated reproducibility across multiple cell types, clear cost‑of‑goods and scale‑up metrics, regulatory pathway clarity for therapeutic uses, and adoption by drug discovery or cell‑therapy developers.[1][4] If those milestones are met, iOrganBio could evolve from a niche platform to a foundational infrastructure provider for programmable biology—lowering variability for many downstream ventures and accelerating translational pipelines.[4][3]
If you’d like, I can:
iOrganBio has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $2.0M Seed | Draper Associates, First Star Ventures, Hustle Fund, Innospark Ventures, Locus Ventures |